Skip to main content

Table 2 Adverse events reported by ≥30% of patients overall, by maximum reported grade

From: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

  Evaluable patients, n (%)
  Cohort 1 Cohort 2 Overall
  (n = 9) (n = 10) (n = 19)
  Grade 1/2 Grade ≥3 Grade 1/2 Grade ≥3  
Diarrhea 6 (67) 0 6 (60) 0 12 (63)
Nausea 5 (56) 0 6 (60) 0 11 (58)
Neutropenia 3 (33) 4 (44)a 2 (20) 2 (20)b 11 (58)
Alopecia 6 (67) 0 4 (40) 0 10 (53)
Fatigue 6 (67) 0 3 (30) 1 (10) 10 (53)
Anemia 3 (33) 2 (22) 1 (10) 0 6 (32)
Constipation 4 (44) 0 2 (20) 0 6 (32)
Peripheral neuropathy 3 (33) 0 3 (30) 0 6 (32)
Rash 1 (11) 0 5 (50) 0 6 (32)
Vomiting 3 (33) 0 3 (30) 0 6 (32)
  1. aIncludes one grade 4 event.
  2. bIncludes one case of febrile neutropenia.